Inari Medical Inc. [NASDAQ: NARI] jumped around 10.83 points on Wednesday, while shares priced at $95.94 at the close of the session, up 12.72%. The company report on January 13, 2021 that Inari Medical Reports Preliminary Fourth Quarter 2020 Revenue.
Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, reported preliminary unaudited fourth quarter 2020 revenue.
Preliminary Fourth Quarter Revenue and Business Highlights:.
Inari Medical Inc. stock is now 9.91% up from its year-to-date (YTD) trading value. NARI Stock saw the intraday high of $98.09 and lowest of $88.40 per share. The company’s 52-week high price is 88.75, which means current price is +24.00% above from all time high which was touched on 01/13/21.
Compared to the average trading volume of 609.20K shares, NARI reached a trading volume of 1670148 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Inari Medical Inc. [NARI]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NARI shares is $88.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NARI stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wells Fargo have made an estimate for Inari Medical Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on December 15, 2020. While these analysts kept the previous recommendation, BTIG Research raised their target price to Buy. The new note on the price target was released on November 18, 2020, representing the official price target for Inari Medical Inc. stock. Previously, the target price had yet another raise from $66 to $76, while Morgan Stanley kept a Overweight rating on NARI stock.
The Average True Range (ATR) for Inari Medical Inc. is set at 4.49, with the Price to Sales ratio for NARI stock in the period of the last 12 months amounting to 40.63. The Price to Book ratio for the last quarter was 24.23, with the Price to Cash per share for the same quarter was set at 3.58.
How has NARI stock performed recently?
Inari Medical Inc. [NARI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 20.82. With this latest performance, NARI shares gained by 43.52% in over the last four-week period, additionally plugging by 77.11% over the last 6 months.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NARI stock in for the last two-week period is set at 76.28, with the RSI for the last a single of trading hit 80.32, and the three-weeks RSI is set at 72.39 for Inari Medical Inc. [NARI]. The present Moving Average for the last 50 days of trading for this stock 73.63, while it was recorded at 86.23 for the last single week of trading.
Inari Medical Inc. [NARI]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Inari Medical Inc. [NARI] shares currently have an operating margin of +1.80 and a Gross Margin at +88.59. Inari Medical Inc.’s Net Margin is presently recorded at -2.33.
Return on Total Capital for NARI is now 3.08, given the latest momentum, and Return on Invested Capital for the company is -3.98. Return on Equity for this stock declined to -7.81, with Return on Assets sitting at -3.30. When it comes to the capital structure of this company, Inari Medical Inc. [NARI] has a Total Debt to Total Equity ratio set at 129.64. Additionally, NARI Total Debt to Total Capital is recorded at 56.45, with Total Debt to Total Assets ending up at 43.73.
Reflecting on the efficiency of the workforce at the company, Inari Medical Inc. [NARI] managed to generate an average of -$5,989 per employee. Receivables Turnover for the company is 7.56 with a Total Asset Turnover recorded at a value of 1.42.Inari Medical Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 13.40 and a Current Ratio set at 13.90.
Insider trade positions for Inari Medical Inc. [NARI]
There are presently around $832 million, or 53.40% of NARI stock, in the hands of institutional investors. The top three institutional holders of NARI stocks are: ALLIANCEBERNSTEIN L.P. with ownership of 1,338,068, which is approximately 42.74% of the company’s market cap and around 3.90% of the total institutional ownership; PERCEPTIVE ADVISORS LLC, holding 848,500 shares of the stock with an approximate value of $81.41 million in NARI stocks shares; and VANGUARD GROUP INC, currently with $79.24 million in NARI stock with ownership of nearly 62.028% of the company’s market capitalization.
Positions in Inari Medical Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 74 institutional holders increased their position in Inari Medical Inc. [NASDAQ:NARI] by around 3,501,627 shares. Additionally, 46 investors decreased positions by around 2,229,598 shares, while 10 investors held positions by with 2,941,546 shares. The mentioned changes placed institutional holdings at 8,672,771 shares, according to the latest SEC report filing. NARI stock had 50 new institutional investments in for a total of 1,373,974 shares, while 30 institutional investors sold positions of 1,055,699 shares during the same period.